FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
To develop a biodegradable polymeric drug delivery system for the treatment of ovarian cancer with the capacity for non-invasive fate monitoring, we designed and synthesized N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-epirubicin (EPI) conjugates. The polymer backbone was labeled with acceptor fluorophore Cy5, while donor fluorophores (Cy3 or EPI) were attached to HPMA copolymer side chains via an enzyme-cleavable GFLG linker. This design allows elucidating separately the fate of the drug and of the polymer backbone using fluorescence resonance energy transfer (FRET). The degradable diblock conjugate (2P-EPI) was synthesized by reversible addition-fragmentation chain transfer (RAFT) polymerization using a bifunctional chain transfer agent (Peptide2CTA). The pharmacokinetics (PK) and therapeutic effect of 2P-EPI (Mw~100kDa) were determined in mice bearing human ovarian carcinoma A2780 xenografts. Compared to 1st generation conjugate (P-EPI, Mw<50kDa), 2P-EPI demonstrated remarkably improved PK such as four-fold terminal half-life (33.22±3.18 h for 2P-EPI vs. 7.55±3.18 h for P-EPI), which is primarily attributed to the increased molecular weight of the polymer carrier. Notably, complete tumor remission and long-term inhibition of tumorigenesis (100 days) were achieved in mice (n=5) treated with 2P-EPI. Moreover, in vitro cell uptake and intracellular drug release were determined via FRET intensity changes. The results establish a solid foundation for future in vivo tracking of drug delivery and chain scission of polymeric conjugates by FRET imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Structure and properties of pharmacologically active polymers
Ringsdorf, H. (1975) · Journal of Polymer Science: Polymer Symposia · doi:10.1002/polc.5070510111 · Cited by 1,094
Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223 · cited 1×
“in human ovarian cancer cells, but decreased cardiotoxicity and myelotoxicity than DOX at equimolar doses [22].”
Background
Cited by
Diverse Applications of Nanomedicine
Pelaz, B., Alexiou, C., Alvarez-Puebla, R. A., Alves, F., Andrews, A. M., Ashraf, S., Balogh, L. P., Ballerini, L., Bestetti, A., Brendel, C., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b06040 · Cited by 1,350
Self-citationHarnessing Endogenous Stimuli for Responsive Materials in Theranostics
Cook, A. B., & Decuzzi, P. (2021) · ACS Nano · doi:10.1021/acsnano.0c09115 · Cited by 262
Chen, T., He, B., Tao, J., He, Y., Deng, H., Wang, X., & Zheng, Y. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.04.009 · Cited by 186
Cathepsin-sensitive nanoscale drug delivery systems for cancer therapy and other diseases
Dheer, D., Nicolas, J., & Shankar, R. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.010 · Cited by 144
“fluorophore) or epirubicin (EPI) through a GFLG linker and evaluated by FRET during cell uptake and intracellular drug delivery experiments (Figure 22) [172].”
Method
Metadata
- Authors
- Yang, J., Zhang, R., Radford, D. C., & Kopeček, J.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 218
- Pages
- 36-44
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1946895920
- Cited by
- 62
- References
- 3
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. https://app.cochat.ai/papers/10.1016/j.jconrel.2015.09.045
- The paper
- Yang, J., Zhang, R., Radford, D. C., & Kopeček, J. (2015). FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2015.09.045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.